Learn how to implement smart manufacturing and build a Connected Enterprise at annual event hosted by Rockwell Automation MILWAUKEE - Friday, September 16th 2016 [ME NewsWire] (BUSINESS WIRE)-- Registration is now open for the 25th Automation Fair event hosted by Rockwell Automation and members of its PartnerNetwork program. Manufacturers and producers across the globe can see the latest products, services and solutions that help enable a Connected Enterprise at this year’s event, being held at the Georgia World Congress Center on Nov. 9 and 10 in Atlanta. “We are well-positioned to bring The Connected Enterprise to life for our customers, given our technology, domain expertise, partners and market access,” says Blake Moret, president and CEO, Rockwell Automation. “You can see the power of this combination at the Automation Fair event. As a company, we continue to focus all of our passion and knowledge on helping our customers improve their competitiveness.” Automation Fair Event ... Read more »

Les nouveaux contrôleurs eSBC redéfinissent le futur des communications tout IP. Équipés de 2 à 8 ports de téléphonie, les eSBC de Patton effectuent le travail de plusieurs dispositifs, pour la moitié du coût. GAITHERSBURG, Maryland - Mardi 13 Septembre 2016 [ME NewsWire] SmartNode™ VoIP... more than just talk! (BUSINESS WIRE)--Patton Electronics, fabricant américain de solutions de communications unifiées, de cloud et d'IoT destinées aux opérateurs, aux entreprises et aux industriels, propose à présent une nouvelle gamme de contrôleurs de périphérie de session (eSBC) SmartNode économiques et haute performance équipés de deux à huit interfaces téléphoniques. Un eSBC conventionnel fournit uniquement une communication tout IP, SIP vers SIP, et la conversion de l'analogique ou de l'ISDN vers la téléphonie IP doit être assurée par une passerelle média VoIP séparée. En fusionnant les fonctions de la passerelle média avec les capacités d'un eSBC de pointe en un seul en même dispositif éc ... Read more »

Glyxambi® is a single tablet that combines Jardiance® and Trajenta® and has been shown to improve blood sugar control in adults with type 2 diabetes INGELHEIM, Germany & INDIANAPOLIS, Indiana - Saturday, September 17th 2016 [ME NewsWire] (BUSINESS WIRE)-- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). Glyxambi®, from the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance, is a single tablet combining Jardiance® (empagliflozin), a sodium glucose co-transporter-2 (SGLT2) inhibitor, and Trajenta® (linagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor. This recommendation is based on data from three Phase III clinical trials evaluating the efficacy and safety of Glyxambi® in patients with T2D. The CHMP positive opinion recommends Glyxambi®, fixed dose combination of Jardiance® and Trajenta®, for use in ad ... Read more »

Ozanimod demonstrated continued efficacy over 96 weeks on MRI and clinical measures of multiple sclerosis disease activity BOUDRY, Switzerland - Friday, September 16th 2016 [ME NewsWire] No new safety or tolerability issues were identified during the ongoing blinded extension (BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposure on treatment) of the RADIANCE phase 2 trial of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). The results were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which is being held in London from September 14-17, 2016. “The data from this blinded extension are encouraging and further support evaluation of the benefit-risk profile of ozanimod in th ... Read more »

− If authorized, NINLARO will provide a new treatment option for European patients with multiple myeloma who have received at least one prior therapy – CAMBRIDGE, Mass. & OSAKA, Japan - Friday, September 16th 2016 [ME NewsWire] − Opinion based on TOURMALINE-MM1 trial, in which NINLARO plus lenalidomide and dexamethasone demonstrated 6 month improvement in progression-free survival versus the placebo regimen − (BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the conditional approval of NINLAROTM (ixazomib) capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. If the European Commission ratifies the CHMP’s opinion and authorization is granted, NINLARO will be the first and only oral proteasome inhibitor ... Read more »